Psychopaths are most likely to live in these US states
The research analyzed data from 1.8 million people across 183 countries, including 144,000 in the U.S., linking personality traits to societal factors like poverty, inequality, and violence.
Researchers found that in societies where rules are broken and conditions are poor, individuals tend to prioritize self-interest, leading to higher 'Dark Factor' levels.
U.S. states such as Louisiana, Mississippi, Texas, Nevada and New York were identified with higher 'Dark Factor' levels, while Utah, Vermont, and Alaska showed lower levels.
The study suggests that personality is shaped by societal conditions, implying that reforms to reduce corruption and inequality could help prevent the development of negative personality traits.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
8 minutes ago
- The Guardian
How the Trump administration made a sewage crisis ‘woke'
Like hundreds of families across Lowndes County, Alabama, the McPhersons do not have access to proper sanitation – just a pipe carrying raw sewage a short distance from their home. For a country that is one of the richest in the world, it is a public health scandal. 'There's a chance if you don't watch yourself, everything will shoot down with force and get all over you,' says Christopher McPherson. Nina Lakhani, a senior reporter for Guardian US, explains to Nosheen Iqbal that Lowndes County is one of the poorest districts in the country and has a history of brutal cotton plantation enslavement and also the civil rights and Black power movements. They discuss the way the soil has affected access to sanitation in the county, the significant health and psychological problems that have followed, and the long struggle for justice in which a landmark civil rights ruling under the Biden administration has been overturned by the actions of Donald Trump. Support the Guardian today:
Reuters
3 hours ago
- Reuters
Vertex's trial failure, scrapped study cloud pain drug push; shares slump
Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of its approved pain drug, sending its shares down 14.4% after the bell. The company (VRTX.O), opens new tab has been diversifying into gene therapies and non-opioid painkillers as it looks to reduce its reliance on cystic fibrosis drugs, a market it dominates. Unlike opioids, which trigger the brain's reward centers, making them an addiction risk, Vertex's drugs block pain signals at the origin, providing a lucrative opportunity for the company. The next-generation non-opioid painkiller, called VX-993, reduced pain by 74.5 points over 48 hours, compared with 50.2 points in the placebo group, but the difference was not statistically significant, Vertex said. The company tested acute pain reduction in patients who had bunionectomy, a surgery to correct deformed bones of the big toe and foot. The drug was found to be generally safe, with most side effects being mild to moderate and no serious problems linked to the painkiller, the company said. Wall Street analysts and investors have been keenly watching the results of the trial, as Vertex seeks to expand beyond Journavx, its non-opioid approved by the U.S. Food and Drug Administration in January for acute pain. Separately, Vertex also said it would not start a study for Journavx to treat a type of nerve pain in the lower back and legs following discussion with the FDA. Leerink Partners analyst David Risinger said Vertex's pain portfolio updates were "disappointing," despite reporting second-quarter results that were above expectations. Vertex plans to prioritize testing of, and later seeking approval for, Journavx to treat a type of nerve pain in diabetic patients. It will also seek to secure approval for other types of nerve pain, the company said in its earnings press release.
The Independent
3 hours ago
- The Independent
Colorectal cancer rates in the US have increased ‘steeply', research finds
Research indicates a steep rise in colorectal cancer rates among younger adults in the U.S., with a 50 percent relative increase observed between 2021 and 2022. The recommended screening age was lowered from 50 to 45 in 2021 to encourage earlier detection, as early onset cases have nearly doubled in young adults under 55 over the past decade. Colorectal cancer is the third leading cause of cancer deaths in the U.S., with over 154,000 new cases projected for this year. While theories such as poor nutritional health and gut toxins are being explored, researchers have not yet identified a definitive cause for the surge in cases. Experts predict that by 2030, colorectal cancer could become the leading cause of cancer death for individuals under 50, highlighting the need for increased public awareness and screening.
